Sanofi’s CEO Departure Will Leave Investors Reeling

Sanofi has delivered a one-two punch to investors, following up news that sales of its largest diabetes drug are slowing sharply with Wednesday’s unceremonial dismissal of Chief Executive Chris Viehbacher.

Since 2008, Mr. Viehbacher has overhauled the French drug company, making it a credible...